Alzheimer’s Disease: The Promise and Challenges of Emerging Biomarkers and Treatments
Berlin, Germany — The fight against Alzheimer’s disease, a condition affecting nearly 55 million people worldwide, is entering a transformative phase. Recent breakthroughs in biomarker research and disease-modifying therapies are offering new hope for early detection and intervention, even as debates persist over the real-world efficacy and accessibility of these innovations. For decades, treatment options for Alzheimer’s have been limited to managing symptoms rather than addressing the underlying causes of the disease. Now, scientists and clinicians are shifting focus toward therapies that target the biological mechanisms driving neurodegeneration, with biomarkers playing a pivotal role in diagnosing and monitoring the disease at its earliest stages.
This shift is not without controversy. Even as regulatory agencies like the U.S. Food and Drug Administration (FDA) and Health Canada have approved new treatments targeting amyloid plaques—a hallmark of Alzheimer’s—critics argue that the clinical benefits of these drugs remain modest and arrive with significant risks. Meanwhile, researchers are exploring alternative pathways, including tau protein tangles and neuroinflammation, to develop more effective and safer therapies. As the global population ages, the urgency to find solutions has never been greater, but the path forward is fraught with scientific, ethical, and logistical challenges.
Biomarkers: The Key to Early Detection
One of the most significant advancements in Alzheimer’s research is the development of biomarkers—measurable indicators of disease presence or progression. These biomarkers, detectable through blood tests, cerebrospinal fluid (CSF) analysis, or advanced imaging techniques like positron emission tomography (PET) scans, are revolutionizing how clinicians diagnose and monitor Alzheimer’s. Traditionally, Alzheimer’s was diagnosed based on cognitive symptoms, often at a stage when significant brain damage had already occurred. Biomarkers now allow for earlier and more accurate detection, even before symptoms appear.
A landmark study published in Nature Medicine in 2023 demonstrated that blood-based biomarkers, such as phosphorylated tau (p-tau) and neurofilament light chain (NfL), could predict Alzheimer’s with high accuracy. These tests are less invasive and more cost-effective than traditional methods like CSF analysis or PET scans, making them more accessible to a broader population. The study found that elevated levels of p-tau217 in blood plasma were strongly associated with amyloid plaque accumulation in the brain, a key pathological feature of Alzheimer’s. This breakthrough has paved the way for large-scale screening programs, particularly for individuals at higher risk due to genetic factors or family history (Nature Medicine, 2023).
In Canada, researchers at the University of Toronto and St. Michael’s Hospital have been at the forefront of biomarker research. A 2024 study published in the Canadian Medical Association Journal (CMAJ) highlighted the potential of biomarkers to improve early diagnosis and treatment outcomes for the Canadian population. The study, led by Dr. Jennifer A. Watt and colleagues, emphasized that while biomarkers are not yet a standalone diagnostic tool, they are a critical component of a comprehensive diagnostic approach. The authors noted that integrating biomarkers into clinical practice could facilitate identify patients who would benefit most from emerging disease-modifying therapies (CMAJ, 2024).
Disease-Modifying Therapies: A New Era of Treatment
For decades, the standard of care for Alzheimer’s has been limited to cholinesterase inhibitors (e.g., donepezil) and memantine, drugs that temporarily alleviate symptoms but do not alter the course of the disease. The approval of aducanumab (Aduhelm) by the FDA in 2021 marked a turning point, as it was the first disease-modifying therapy targeting amyloid plaques. However, its approval was controversial due to mixed clinical trial results and concerns over its high cost and potential side effects, including brain swelling and bleeding.
Since then, two additional amyloid-targeting drugs have received regulatory approval: lecanemab (Leqembi) and donanemab. Lecanemab, developed by Eisai and Biogen, was approved by the FDA in 2023 and has shown promise in slowing cognitive decline in patients with early-stage Alzheimer’s. In a Phase 3 clinical trial, lecanemab reduced cognitive decline by 27% over 18 months compared to a placebo, a statistically significant but modest effect. The drug works by binding to soluble amyloid-beta protofibrils, preventing them from aggregating into plaques (New England Journal of Medicine, 2023).
Donanemab, developed by Eli Lilly, has too shown encouraging results in clinical trials. In a 2023 study published in JAMA, donanemab slowed cognitive decline by 35% in patients with early Alzheimer’s over 18 months. The drug targets a specific form of amyloid plaque called N3pG, which is believed to be particularly toxic to neurons. Despite these promising findings, both lecanemab and donanemab come with significant risks, including amyloid-related imaging abnormalities (ARIA), which can cause brain swelling and microhemorrhages. These side effects have raised concerns among clinicians and patient advocates about the drugs’ safety profiles (JAMA, 2023).
In Canada, the approval and availability of these drugs have been slower. Health Canada approved lecanemab in 2024, but its rollout has been limited by provincial funding decisions and concerns over cost-effectiveness. The Alzheimer Society of Canada has emphasized that these therapies are not a cure but represent a step forward in the fight against Alzheimer’s. The organization has called for increased investment in research and healthcare infrastructure to ensure equitable access to these treatments (Alzheimer Society of Canada).
Controversies and Challenges
Despite the optimism surrounding these new treatments, their real-world impact remains a subject of intense debate. A 2025 meta-analysis published in The Lancet Neurology cast doubt on the long-term efficacy of amyloid-targeting therapies, suggesting that their benefits may diminish over time and that the risks of side effects could outweigh the advantages for some patients. The analysis, which reviewed data from multiple clinical trials, found that while these drugs slowed cognitive decline in the short term, their effects were not sustained beyond 24 months. The authors called for further research into alternative therapeutic targets, such as tau protein and neuroinflammation (The Lancet Neurology, 2025).
Another major challenge is the accessibility of these treatments. The high cost of amyloid-targeting drugs—estimated at $26,500 per year for lecanemab in the U.S.—poses a significant barrier to widespread adoption. In Canada, provincial health systems have been hesitant to cover these therapies without clear evidence of long-term cost-effectiveness. A report by the Canadian Agency for Drugs and Technologies in Health (CADTH) in 2024 recommended against public funding for lecanemab, citing insufficient evidence of its benefits relative to its costs. This decision has sparked criticism from patient advocacy groups, who argue that delaying access to these treatments could deny patients the opportunity to benefit from early intervention (CADTH, 2024).
Ethical concerns have also emerged regarding the use of biomarkers and early diagnosis. While early detection can enable timely intervention, it also raises questions about the psychological impact of a diagnosis before symptoms appear. A 2024 study in Alzheimer’s & Dementia found that individuals who received a biomarker-based diagnosis of preclinical Alzheimer’s experienced increased anxiety and depression, highlighting the require for comprehensive counseling and support services alongside diagnostic testing (Alzheimer’s & Dementia, 2024).
Beyond Amyloid: Exploring New Therapeutic Targets
While amyloid-targeting therapies have dominated the headlines, researchers are increasingly exploring alternative pathways to combat Alzheimer’s. One promising area of research is the role of tau protein, which forms tangles inside neurons and is closely associated with cognitive decline. Several tau-targeting therapies are currently in clinical trials, including gosuranemab and tilavonemab, which aim to prevent tau aggregation and spread within the brain.
Another emerging target is neuroinflammation, which is believed to play a key role in the progression of Alzheimer’s. Drugs like sargramostim, a granulocyte-macrophage colony-stimulating factor (GM-CSF), are being investigated for their potential to reduce inflammation and improve cognitive function. Early-phase trials have shown promising results, with sargramostim demonstrating the ability to enhance immune responses and reduce amyloid plaques in the brain (Nature Medicine, 2023).
Gene therapy is also being explored as a potential treatment for Alzheimer’s. Researchers at the University of California, San Diego are investigating the use of adeno-associated virus (AAV) vectors to deliver genes that promote neuronal survival and reduce amyloid production. While still in the early stages of development, gene therapy holds the potential to provide long-lasting protection against neurodegeneration.
What’s Next for Alzheimer’s Research and Treatment?
The next few years will be critical for Alzheimer’s research, as scientists and clinicians work to refine existing therapies and develop new ones. The World Health Organization (WHO) has identified Alzheimer’s and other dementias as a global health priority, calling for increased investment in research, healthcare infrastructure, and public awareness. In 2025, the WHO launched the Global Action Plan on Dementia, which aims to improve the lives of people with dementia and their caregivers through a coordinated international response (WHO, 2025).
For patients and families affected by Alzheimer’s, the advancements in biomarkers and disease-modifying therapies offer a glimmer of hope. However, the road ahead is complex, with challenges ranging from scientific uncertainties to ethical dilemmas and access barriers. As research continues to evolve, the focus must remain on developing treatments that are not only effective but also safe, affordable, and accessible to all who need them.
The next major milestone in Alzheimer’s research will be the results of ongoing Phase 3 clinical trials for tau-targeting therapies and neuroinflammation drugs, expected in late 2026 and early 2027. These trials could provide further insights into the mechanisms of the disease and pave the way for more targeted and effective treatments.
For now, patients and caregivers are encouraged to stay informed through trusted sources like the Alzheimer’s Association and Alzheimer Society of Canada, which provide up-to-date information on research, clinical trials, and support services. As the field continues to advance, collaboration between researchers, clinicians, policymakers, and patient advocates will be essential to ensuring that the promise of these innovations translates into real-world benefits.
What are your thoughts on the future of Alzheimer’s treatment? Do you believe biomarkers and disease-modifying therapies will revolutionize care, or do the challenges outweigh the benefits? Share your perspective in the comments below and join the conversation on social media.